3 Of My Top ISA Picks: AstraZeneca plc, Legal & General Group Plc And Burberry Group plc

These 3 stocks look set to post stellar returns: AstraZeneca plc (LON: AZN), Legal & General Group Plc (LON: LGEN) and Burberry Group plc (LON: BRBY).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Investor sentiment in Burberry (LSE: BRBY) seems to be on the up, with the luxury lifestyle brand recording a rise in its share price of 11% since the turn of the year.

Clearly, at least some of this is due to reduced investor fear in recent weeks regarding the prospects for China, which remains a key market for Burberry. But with the company also having upbeat growth potential, it seems as though now could be a good time to buy it for the long term.

For example, Burberry is forecast to return to growth in the next financial year, with an 8% increase in earnings pencilled-in for the following year. And with the Chinese economy becoming increasingly consumer-focused, Burberry’s profit growth could be much higher over the medium-to-long term.

Certainly, the company’s shares seem to deserve a higher rating than their current price-to-earnings (P/E) ratio of 18.5, with Burberry’s high degree of customer loyalty providing it with a wide economic moat. Therefore, even though they’ve risen already this year, shares in Burberry seem to be worth considering for inclusion in an ISA.

Bight prospects

Similarly, Legal & General (LSE: LGEN) also appears to offer sound long-term total return prospects. It currently yields 6.2% and with dividends being covered 1.4 times by profit, there seem to be bright prospects for dividend growth. In fact, Legal & General is expected to increase shareholder payouts by 7.7% next year, which should easily beat inflation and provide the company’s shares with a positive catalyst.

As well as bright dividend prospects, Legal & General remains a solid value play. Its bottom-line growth forecasts of 9% this year and a further 6% next year don’t appear to be fully factored-in to its share price, with Legal & General currently trading on a P/E ratio of just 11.4. That’s significantly lower than the FTSE 100’s P/E ratio of around 13 and shows that while investor sentiment in Legal & General may be rather weak following its decline of 13% since the start of the year, it remains a very appealing buy for long-term investors.

Strong pipeline

On the topic of long term, AstraZeneca (LSE: AZN) is still on course to reverse its sales decline over the coming years. Investors hoping for a quick return via an acquisition for the pharmaceutical company may be somewhat disappointed though, since the prospects for this seem to have reduced since the US authorities announced their intention to close a tax loophole. However, with AstraZeneca’s own acquisition programme being in full swing, its pipeline appears to be more diversified and stronger than it has been for a considerable period of time.

This should boost the company’s top and bottom lines, thereby providing a positive catalyst for its share price over the long run. And with AstraZeneca yielding 5% despite having not raised dividends in the last five years, it remains a top notch income play which could begin to increase shareholder payouts as its profitability creeps upwards.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of AstraZeneca, Burberry, and Legal & General Group. The Motley Fool UK has recommended AstraZeneca and Burberry. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »

Investing Articles

Investing £5 a day could help me build a second income of £329 a month!

This Fool explains how £5 a day, or one less takeaway coffee, could help her build a monthly second income…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

2 FTSE income stocks investors should consider buying in April

Income stocks are a great way to build wealth. Our writer details two picks she believes investors should consider snapping…

Read more »

Investing Articles

What might the 5-year price chart tell us about BT shares?

Christopher Ruane considers what clues the long-term performance of BT shares might offer him about business performance and whether to…

Read more »